With genetic test spending under the microscope, CMS is asking labs to help shape future anti-fraud rules—before formal proposals are drafted.

Clinical laboratory leaders faced a critical, albeit narrowing, window to influence a significant new federal anti-fraud initiative launched by the Centers for Medicare and Medicaid Services (CMS). The agency’s "CRUSH" Request for Information (RFI) closed its comment period on March 30, marking a pivotal moment for stakeholders to contribute to the foundational framework of future regulations. This proactive engagement strategy from CMS underscores a clear intent to gather industry insights and operational realities before formal rulemaking processes commence, an approach that has been met with both apprehension and an urgent call to action within the diagnostic community.

The Genesis of CRUSH: A Proactive Stance Against Fraud

Published on February 27, the CRUSH RFI, an acronym for Comprehensive Regulations to Uncover Suspicious Healthcare, serves as a clear declaration of CMS’s heightened commitment to strengthening program integrity across all its major healthcare programs: Medicare, Medicaid, and Medicare Advantage. The initiative signals a strategic shift towards more robust, data-driven approaches to detect and prevent fraud, waste, and abuse. Unlike traditional regulatory cycles where industry input often comes after proposed rules have been drafted, the CRUSH RFI offered an unprecedented early opportunity for clinical laboratories, diagnostic manufacturers, healthcare providers, and other interested parties to directly inform the agency’s policy development at its nascent stage. This early consultation aims to ensure that forthcoming regulations are not only effective in combating fraud but also practical and minimally disruptive to legitimate healthcare services. The impending March 30 deadline created a concentrated period of activity for industry associations and individual laboratories to synthesize their operational insights, data, and recommendations for submission.

Genetic Testing Under the Microscope: Alarming Spending Trends

A central and undeniably critical focus of the CRUSH initiative is the burgeoning area of clinical diagnostic testing, particularly genetic and molecular assays. CMS’s intensified scrutiny stems from compelling and, to the agency, alarming federal data that highlights a significant disparity between the volume and cost of genetic tests within the Medicare Part B program. According to recent federal statistics, genetic tests constituted a mere 5% of the total Medicare Part B test volume in 2024. However, despite this relatively low volume, these tests accounted for a staggering 43% of total laboratory spending, translating to an approximate expenditure of $3.6 billion. This disproportionate spending pattern has raised red flags within CMS, signaling a potential vulnerability to fraud, waste, and abuse that demands immediate and comprehensive attention.

The agency further justified its heightened scrutiny by pointing to a consistent stream of ongoing enforcement actions and public fraud alerts specifically tied to laboratory testing. These actions often uncover schemes involving medically unnecessary tests, kickbacks to physicians for referrals, false claims, patient identity theft for billing purposes, and sophisticated arrangements designed to exploit the complexities of genetic testing reimbursement. The high cost per test, coupled with the rapid pace of innovation and the intricate medical necessity criteria associated with genetic testing, creates an environment ripe for exploitation by unscrupulous actors. CMS’s emphasis on these statistics underscores its belief that without proactive intervention, the financial burden on federal healthcare programs will continue to escalate, potentially diverting resources from essential patient care.

Unpacking the Fraud Landscape in Diagnostics

The landscape of diagnostic fraud, particularly in genetic testing, is multifaceted and constantly evolving. Schemes often involve predatory marketing tactics targeting vulnerable seniors, offering "free" genetic tests in exchange for personal information, which is then used to bill Medicare for expensive, often unnecessary, tests. Other common fraudulent activities include:

Medically Unnecessary Testing: Billing for tests that are not ordered by a treating physician or are not relevant to a patient’s current medical condition. This often involves broad-panel genetic tests that include markers for conditions unrelated to the patient’s symptoms or risk factors.
Kickbacks and Inducements: Offering illegal payments or other benefits to physicians, patient recruiters, or beneficiaries themselves in exchange for test referrals. This violates the Anti-Kickback Statute and distorts medical decision-making.
Identity Theft and Phantom Billing: Using stolen patient information to bill for services never rendered or tests never performed.
Upcoding: Submitting claims for more expensive tests or services than those actually provided.
Lack of Documentation: Failing to maintain adequate medical records to support the medical necessity of ordered tests.
Shell Companies and Nominee Owners: Creating complex corporate structures to obscure the true ownership and operation of fraudulent laboratories.

These schemes not only drain billions from federal programs but also pose significant risks to patient safety, privacy, and trust in the healthcare system. Patients may receive inaccurate or misleading test results, have their personal health information compromised, or be subjected to unnecessary medical procedures based on fraudulent test orders. The CRUSH initiative aims to equip CMS with more powerful tools to dismantle these complex fraud networks.

CMS’s Strategic Pillars for Prevention: Analytics, Oversight, and Collaboration

The RFI articulated several strategic avenues through which CMS seeks to enhance its fraud detection and prevention capabilities. The agency is actively soliciting input from laboratories and other stakeholders on specific categories of interventions:

New Regulatory Authorities: CMS is exploring whether existing regulatory frameworks are sufficient or if new authorities are needed. This could involve stricter requirements for laboratory enrollment in Medicare, enhanced documentation standards for medical necessity, more rigorous oversight of marketing practices for genetic tests, or even new certification requirements for specific high-risk diagnostic services. The goal is to create a more robust legal and administrative framework that makes it harder for fraudulent entities to operate within the system.
Advanced Analytics Tools: A significant emphasis is placed on leveraging cutting-edge data analytics. CMS is interested in deploying advanced computational methods, including artificial intelligence (AI) and machine learning (ML) algorithms, to identify suspicious billing patterns, predict potential fraud risks, and flag anomalous claims in real-time. These tools could analyze vast datasets of claims, provider behavior, and patient demographics to detect outliers that human auditors might miss. The agency envisions a system where fraud detection moves from reactive "pay and chase" models to proactive, predictive prevention.
Data-Driven Approaches: Beyond just analytics tools, CMS is looking at how data can inform new operational strategies. This includes accelerating fraud detection earlier in the reimbursement claims lifecycle, potentially moving from predominantly post-payment review to more robust pre-payment review for high-risk claims or providers. Early detection not only saves money but also minimizes the disruption and burden associated with recovering funds from fraudulent activities after they have occurred. CMS is also interested in approaches that integrate data from various sources—claims, enrollment, provider databases, and enforcement actions—to create a more comprehensive view of potential fraud.

By seeking input on these three pillars, CMS aims to develop a multi-pronged strategy that addresses fraud from multiple angles, making the healthcare system more resilient to exploitation.

The MolDX Program: A Critical Review for Broader Application

Another key area of inquiry for clinical laboratories within the CRUSH RFI concerns the Molecular Diagnostic Services (MolDX) program. MolDX is a contractor-led program, primarily managed by Palmetto GBA and Noridian Healthcare Solutions, that provides coverage and payment determinations for molecular diagnostic tests under Medicare. It establishes consistent policies for these complex tests, aiming to ensure appropriate utilization and fair reimbursement.

CMS’s questions regarding MolDX delve into several critical aspects:

Fraud Risk Reduction: The agency is seeking feedback on whether MolDX registration, with its rigorous technical assessment and evidence review processes, effectively reduces fraud risk. Laboratories that participate in MolDX undergo a detailed review of their tests, including analytical and clinical validity, and clinical utility. CMS wants to understand if this process inherently screens out or deters fraudulent submissions.
Payer Requirements Outside Jurisdictions: CMS also inquired why some commercial payers and even Medicare Advantage plans require participation in MolDX, or adherence to its principles, even when a laboratory operates outside a designated MolDX jurisdiction. This observation suggests that other payers perceive value in MolDX’s oversight mechanisms as a fraud prevention or quality assurance tool.

The implications of this inquiry are significant. It raises the possibility of broader adoption of MolDX-like requirements, either through national expansion of the program, integration of its principles into broader CMS regulations, or the establishment of new mandatory oversight requirements tied to molecular test billing. For laboratories, this could mean a more standardized but potentially more burdensome process for test validation, registration, and reimbursement, regardless of their geographic location. It underscores CMS’s interest in leveraging existing successful models to create a more unified and secure framework for molecular diagnostics.

A Narrowing Window: The Regulatory Timeline and Industry Engagement

The March 30 deadline for the CRUSH RFI was a critical juncture. Following the close of the comment period, CMS embarked on a comprehensive review and analysis of all submitted feedback. This phase is crucial, as the agency will distill the myriad perspectives, data points, and recommendations from stakeholders to inform the drafting of formal proposals. The regulatory process typically follows a structured timeline:

RFI Analysis: CMS meticulously reviews all comments received.
Drafting of Proposed Rule: Based on RFI feedback and internal analysis, CMS drafts a Notice of Proposed Rulemaking (NPRM).
Public Comment Period (NPRM): The NPRM is published in the Federal Register, opening another public comment period, typically 60 days, during which stakeholders can provide feedback on specific proposed regulations.
Final Rule Publication: CMS reviews comments on the NPRM, makes any necessary revisions, and then publishes a Final Rule, which becomes binding law.

The proactive nature of the CRUSH RFI means that industry input at this early stage has the potential to significantly shape the direction and substance of the initial proposed rule, potentially preventing the inclusion of impractical or overly burdensome requirements that might otherwise be difficult to amend later in the process. Laboratories that failed to engage missed a unique opportunity to directly influence the foundational principles of these future anti-fraud measures.

Industry Perspectives and Anticipated Reactions

The CRUSH initiative has elicited a range of reactions from various stakeholders within the healthcare ecosystem.

Clinical Laboratory Industry: Industry associations such as the American Clinical Laboratory Association (ACLA), the College of American Pathologists (CAP), and the Association for Molecular Pathology (AMP) likely submitted detailed responses. Their input would have focused on the need for clear, evidence-based regulations that do not stifle innovation or create undue administrative burdens for legitimate laboratories. Concerns would include the potential for over-regulation to impede patient access to essential genetic testing, the administrative costs associated with new compliance requirements, and the importance of distinguishing between legitimate errors and malicious fraud. They would advocate for policies that leverage technology for efficiency while ensuring due process.
Patient Advocacy Groups: These groups would emphasize the importance of protecting patients from fraudulent schemes while simultaneously safeguarding access to medically necessary advanced diagnostics. Their comments would likely highlight the need for patient education, clear communication about testing benefits and risks, and robust protections for patient data privacy.
Healthcare Providers: Physicians and other ordering providers would be interested in the implications for ordering practices, documentation requirements, and potential impacts on clinical workflows. They would likely advocate for policies that simplify the ordering process for legitimate tests and provide clear guidance on medical necessity.
Fraud Investigators and Law Enforcement: These entities would generally welcome stronger regulatory tools and clearer guidelines, which can aid in the investigation and prosecution of healthcare fraud. They would likely support measures that enhance data sharing, improve claims analysis, and provide clearer definitions of fraudulent activities.

The collaborative spirit sought by CMS through the RFI suggests a recognition that effective fraud prevention requires a partnership between regulators and the regulated community, balancing enforcement with the practical realities of delivering healthcare services.

Broader Implications for the Diagnostic Landscape

The implications of the CRUSH initiative extend far beyond just genetic testing, signaling a broader tightening of oversight across the entire diagnostic landscape.

Increased Compliance Burden: Laboratories, especially those performing high-cost, high-complexity testing, can anticipate increased compliance burdens. This will necessitate robust internal controls, enhanced documentation practices, and potentially new investments in compliance staff and technology.
Impact on Innovation: While fraud prevention is critical, industry stakeholders will be keen to ensure that new regulations do not inadvertently stifle innovation in diagnostic development. The balance between oversight and encouraging scientific advancement will be a delicate one for CMS to strike.
Evolving Payment and Reimbursement: Policies affecting enrollment, documentation, payment review, and test validation are all on the table. This could lead to more stringent pre-payment reviews, tighter medical necessity criteria, and potentially changes in reimbursement methodologies for certain tests.
Data Security and Privacy: As CMS emphasizes data analytics, there will be a parallel focus on ensuring the security and privacy of sensitive patient data, particularly genetic information, which is highly personal.
Consolidation in the Industry: Smaller laboratories or those with less robust compliance infrastructures might find it challenging to adapt to new, more stringent regulations, potentially leading to further consolidation within the diagnostic industry.

Looking Ahead: Navigating the Future of Genetic Testing Oversight

As CMS moves forward with analyzing the RFI comments and drafting formal proposals, the diagnostic industry must remain vigilant and prepared. Proactive engagement, even beyond the initial RFI stage, will be crucial. This includes closely monitoring the publication of any proposed rules, actively participating in subsequent comment periods, and preparing internal systems and processes to adapt to forthcoming regulations.

The CRUSH initiative represents a significant step by CMS to safeguard the integrity of federal healthcare programs against the escalating threat of fraud, particularly in the rapidly expanding and high-cost segment of genetic testing. While the goal of preventing fraud is universally supported, the devil will be in the details of the specific regulations. For clinical laboratories, the period following the RFI’s close marks the beginning of a new era of heightened scrutiny and potentially more stringent operational requirements, demanding a strategic and adaptive approach to ensure continued compliance and successful operation within the evolving regulatory landscape.

—Janette Wider